Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

2011/02/01 by Sandra Navarra, Sandra V Navarra, Renato M Guzmán +27 · 2 citations
Medicine · Neuroscience · #Adverse effect #Alternative medicine #Antibody #Autoimmune disease #B cell #B-cell activating factor #Belimumab #Clinical endpoint #Clinical trial #Connective tissue disease #Disease #Immunology #Internal medicine #Lupus erythematosus #Medicine #Multiple Sclerosis Research Studies #Pathology #Placebo #Randomized controlled trial #Systemic Lupus Erythematosus Research #Systemic lupus erythematosus #Vagus Nerve Stimulation Research

paper · doi:10.1016/s0140-6736(10)61354-2

crossref issued 2011/02/01 · crossref published 2011/02/01 · crossref published-print 2011/02/01 · openalex publication_date 2011/02/01 · crossref created 2011/02/05 · crossref deposited 2023/06/04 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05 · crossref indexed 2026/08/06

Citations

• Derivation of the sledai. A disease activity index for lupus patients
• Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus
• A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
• Essai sur les droits de solidarité dans la société internationale contemporaine : vers une troisième génération de droits de l'homme ?

Cited by

• Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials
• Belimumab [wikipedia]